ALPRAZOLAM TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

ALPRAZOLAM

可用日期:

SANIS HEALTH INC

ATC代码:

N05BA12

INN（国际名称）:

ALPRAZOLAM

剂量:

0.50MG

药物剂型:

TABLET

组成:

ALPRAZOLAM 0.50MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Targeted (CDSA IV)

治疗领域:

BENZODIAZEPINES

產品總結:

Active ingredient group (AIG) number: 0115008002; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2021-12-01

产品特点

PRODUCT MONOGRAPH
ALPRAZOLAM
(Alprazolam)
0.25 mg and 0.5 mg Tablets
USP
ANXIOLYTIC - ANTIPANIC
Sanis Health Inc.
Date of Revision:
1 President’s Choice Circle,
June 6, 2019
Brampton, Ontario
L6Y 5S5
www.sanis.com
Control No.: 228154
2
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
5
WARNINGS AND PRECAUTIONS
..............................................................................................
5
ADVERSE REACTIONS
..............................................................................................................
12
DRUG INTERACTIONS
..............................................................................................................
16
DOSAGE AND ADMINISTRATION
..........................................................................................
19
OVERDOSAGE
.............................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
21
STORAGE AND STABILITY
......................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 23
PART II: SCIENTIFIC INFORMATION
...................................................................................
24
PHARMACEUTICAL
INFORMATION......................................................................................
24
CLINICAL TRIALS
...............................................................................